Project Grant R01MH146681
Award Date 8/1/26
Completion Date 4/30/31
Dollars Obligated $294K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Galveston, TX 77555, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $828,340 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate HIV-1 transcription reactivation mechanisms in latent reservoir cells. The research explores the role of transcription factors and Tat protein in initiating and sustaining HIV-1 transcription reactivation, using genetic and genomic approaches to examine HIV-1...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of convergent RNA polymerase II transcription in HIV-1 latency and reactivation. The research aims to define how convergent POL II transcription—specifically antisense and downstream forms originating from the 5'-LTR—regulates sense HIV-1 transcription...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Medical Branch at Galveston $807,498 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to maintain and operate a comprehensive reference center for emerging viruses and arboviruses. The award supports four specific aims: maintaining a comprehensive collection of emerging viruses, arboviruses, and associated reagents including antisera, antigens, and cDNA clones...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $2,461,651 to the University of Texas Health Science Center at Houston under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 18, 2025, for a project extending through July 31, 2029. The project investigates estrogen's impact on immunoglobulin G (IgG) glycomic modulation of immunity and inflammation in people with human immunodeficiency virus (HIV) on antiretroviral...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Maryland Baltimore County $246,070 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the phosphorylation and dephosphorylation of antiretroviral drugs tenofovir and emtricitabine in colonic tissue using mass spectrometry imaging-based enzyme histochemistry. The research addresses variability in clinical...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology (MIT) $553,136 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research visualizing HIV-1 capsid passage through the nuclear pore complex. The funded work addresses how HIV-1 traverses the nuclear pore complex during viral entry into the cell nucleus, a critical stage in the infection process preceding uncoating, reverse transcription, and...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $804,464 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research targeting the super elongation complex to regulate HIV transcription and latency. The research addresses HIV persistence in long-lived latent reservoirs that remain a major barrier to functional cure. The project focuses on developing small molecule regulators of viral transcription as...